Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1b

• Status: Completed
• Trial end date: 2018-11-21
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to confirm that combination of Narlaprevir, Ritonavir and Daclatasvir is safe and highly effective regimen in treatment-naїve patients with chronic hepatitis C (HCV) genotype 1b infection.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: R-Pharm
• Collaborator: Almedis
• Treatments: Ritonavir

Criteria

Inclusion Criteria -

Subjects who meet all of the following criteria are eligible for participation in the study:

• Are willing and able to provide written informed consent.

• Have confirmed chronic HCV infection as documented by:

1. positive anti-HCV antibody (Ab) test or

2. positive HCV RNA or

3. positive HCV genotyping test at least 6 months prior to the Baseline/Day 1 visit.

• Have HCV genotype 1b at screening as determined by the Central Laboratory. Any non definitive results must exclude the subject from study participation.

• Minimum HCV-RNA level of ≥10,000 IU at baseline.

• No evidence of cirrhosis; availability at Baseline of at least one of the following tests, negative results:

1. Liver biopsy within 2 years of screening showing absence of cirrhosis;

2. Fibroscan with a result of ≤ 12.5 kPa within 6 months of baseline/Day1;

3. FibroTest score of ≤ 0.48 AND APRI of ≤ 1 performed during screening. In the absence of a definitive diagnosis of the presence or absence of cirrhosis by the above criteria, a liver biopsy was required. Liver biopsy results supersede the results obtained by Fibroscan or FibroTest.

• Have a screening electrocardiogram (ECG) without clinically significant abnormalities (P wave < 0.1 s; PQ interval 0,12-0,2 s; QRS complex 0,06-0,1 s; QT interval 0,35-0,49 s).

• Must have the following laboratory parameters at screening:

1. alanine aminotransferase (ALT) ≤ 10 x the upper limit of normal (ULN);

2. aspartate aminotransferase (AST) ≤ 10 x ULN;

3. Hemoglobin ≥ 12g/dL for male, ≥ 11g/dL for female subjects;

4. Platelets ≥ 50,000cells/mm3;

5. International normalized ratio (INR) ≤ 1.5 x ULN unless subject has known hemophilia or is stable on an anticoagulant regimen affecting INR;

6. Albumin ≥ 3g/dL;

7. Direct bilirubin ≤ 1.5 x ULN;

8. Hemoglobin A1c (HbA1c) ≤ 10%;

9. Creatinine clearance (CLcr) ≥ 60 mL/min, as calculated by the Cockcroft-Gault equation;

10. Have not been treated with any investigational drug or device within 30 days of the screening visit.

• A female subject is eligible to enter the study if it is confirmed that she is:

1. Not pregnant or nursing;

2. Of non-childbearing potential (i.e., women who have had a hysterectomy, both ovaries removed, or medically documented ovarian failure, or are postmenopausal women >50 years of age with cessation [for ≥12 months] of previously occurring menses), or

3. Of childbearing potential (i.e., women who had not had a hysterectomy, both ovaries removed, or medically documented ovarian failure). Women ≤ 50 years of age with amenorrhea are considered to be of childbearing potential. These women must have a negative serum pregnancy test at screening and a negative urine pregnancy test on the baseline/Day 1 visit prior to enrollment. They must also agree to one of the following from 3 weeks prior to baseline/Day 1 until 6 months after last dose of the investigational drugs:

1. Complete abstinence from intercourse. Periodic abstinence from intercourse (e.g., calendar, ovulation, sympto thermal, post-ovulation methods) is not permitted Or

2. Consistent and correct use of 1 of the following methods of birth control listed below in addition to a male partner who correctly uses a condom from the date of screening until 6 months after the last dose of the investigational drugs:

• intrauterine device (IUD) with a failure rate of < 1% per year;

• female barrier method: cervical cap or diaphragm with spermicidal agent;

• tubal sterilization;

• vasectomy in male partner; Women of childbearing potential must not rely on hormone-containing contraceptives as a form of birth control during the study. Female subjects using a hormone-containing contraceptive prior to screening must stop their contraceptive regimen use from the date of screening until 6 months after their last dose of investigational drugs.

• All male study participants must agree to consistently and correctly use a condom, while their female partner agrees to use either 1 of the non hormonal methods of birth control listed above or a hormone-containing contraceptive listed below, from the date of screening until 6 months after their last dose of investigational drugs:

• implants of levonorgestrel;

• injectable progesterone;

• oral contraceptives (either combined or progesterone only);

• contraceptive vaginal ring;

• transdermal contraceptive patch;

• Male subjects must agree to refrain from sperm donation for at least 6 months after the last dose of investigational drugs.

• Are in generally good health as determined by the investigator.

• Are able to comply with the dosing instructions for study drug administration and are able to complete the study schedule of assessments.

Exclusion Criteria -

Subjects with any of the following are not eligible for participation in the study:

• Had prior exposure to IFN, RBV, or other approved or experimental DAA targeting the HCV.

• Had prior exposure to amiodarone within 24 months before the screening

• Are pregnant or nursing female or male with pregnant female partner.

• Сhronic liver disease of a non-HCV etiology (e.g., hemochromatosis, Wilson's disease, α1-antitrypsin deficiency, cholangitis).

• Are infected with hepatitis B virus (HBV) or human immunodeficiency virus (HIV).

• Have history of malignancy diagnosed or treated within 5 years; subjects under evaluation for malignancy are not eligible.

• Have chronic use of systemically administered immunosuppressive agents (e.g., prednisone equivalent > 10 mg/day).

• Have clinically relevant drug or alcohol abuse within 12 months of screening. A positive drug screen must exclude subjects unless it can be explained by a prescribed medication; the diagnosis and prescription must be approved by the investigator.

• Have excessive alcohol consumption, defined as more than 3 drinks on any single day and more than 7 drinks per week for females, and > than 4 drinks on any single day and more than 14 drinks per week for males.

• Have history of solid organ transplantation.

• Have history of clinically significant illness or any other major medical disorder that may interfere with subject treatment, assessment, or compliance with the protocol by Investigators' opinion.

• Have history of a gastrointestinal disorder (or postoperative condition) that can interfere with the absorption of the study drug.

• Have history of difficulty with blood collection and/or poor venous access for the purposes of phlebotomy.

• Usage of any prohibited concomitant medications as described in the protocol (list of drugs with expected drug-drug interactions due to concomitant ritonavir usage)

• Have known hypersensitivity to the study investigational medicinal product, the metabolites, or formulation excipients.

• Chronic HCV genotype 1b-infected participant who has the presence of genetic variants coding for the NS5A-Y93 С/H/N/S and/or L31 F/M/V/I amino acid substitutions at Screening.